Home >> Marketplace Directory >> Preclinical results for infectious disease test, 2/13:110

Preclinical results for infectious disease test, 2/13:110

image_pdfCreate PDF

 

Akonni Biosystems recently announced results from three preclinical studies verifying the efficacy of its TruDiagnosis molecular diagnostic platform. Akonni TruArray tests are for mid-multiplex molecular diagnostics deployed in near point-of-care settings.

These studies, including those for methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Mycobacterium tuberculosis (MDR-TB), and influenza subtyping, were funded and developed over the past six years by the National Institutes of Health, Centers for Disease Control and Prevention, National Science Foundation, and the Department of Defense.

In collaboration with Johns Hopkins University, Akonni conducted a retrospective study on 87 clinical isolates and 246 nasal swab samples acquired from a non-random, high-risk patient population. Of the 87 isolates, the TruArray test accurately classified 86 (98.8 percent) and correctly identified 14 mecA dropout specimens that were falsely positive in other tests. The overall prevalence of MRSA in the clinical sample set was 16.7 percent.

CAP TODAY
X